Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Leases (2019 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Current Leases for 7 consecutive years, with $5.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Leases rose 2.65% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Jun 2025, up 2.65%, and an annual FY2024 reading of $5.3 million, up 9.27% over the prior year.
  • Current Leases was $5.2 million for Q2 2025 at Bicycle Therapeutics, down from $5.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.5 million in Q1 2025 and bottomed at $182000.0 in Q3 2024.
  • Average Current Leases over 5 years is $3.4 million, with a median of $3.9 million recorded in 2022.
  • The sharpest move saw Current Leases soared 323.16% in 2022, then plummeted 96.1% in 2024.
  • Year by year, Current Leases stood at $2.4 million in 2021, then surged by 31.14% to $3.1 million in 2022, then soared by 56.03% to $4.9 million in 2023, then rose by 9.27% to $5.3 million in 2024, then fell by 1.78% to $5.2 million in 2025.
  • Business Quant data shows Current Leases for BCYC at $5.2 million in Q2 2025, $5.5 million in Q1 2025, and $5.3 million in Q4 2024.